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Background: TTC19 deficiency is a progressive neurodegenerative disease associated with isolated mitochondrial
respiratory chain (MRC) complex III deficiency and loss-of-function mutations in the TT19 gene in the few patients
reported so far.
Methods: We performed exome sequencing and selective mutational analysis of TTC19, respectively, in patients
from three unrelated families presenting with initially unspecific clinical signs of muscular hypotonia and global
developmental delay followed by regression, ataxia, loss of speech, and rapid neurological deterioration. One
patient showed severe lactic acidosis at the neonatal age and during intercurrent illness.
Results: We identified homozygous mutations in all three index cases, in two families novel missense mutations
(c.544 T > C/p.Leu185Pro; c.917 T > C/p.Leu324Pro). The younger sister of the severely affected patient 3 showed
only mild delay of motor skills and muscular hypotonia so far but is also homozygous for the same mutation.
Notably, one patient revealed normal activities of MRC complex III in two independent muscle biopsies.
Neuroimaging of the severely affected patients demonstrated lesions in putamen and caudate nuclei, cerebellar
atrophy, and the unusual finding of hypertrophic olivary nuclei degeneration. Reviewing the literature revealed
striking similarities regarding neuroimaging and clinical course in pediatric patients with TTC19 deficiency: patterns
consistent with Leigh or Leigh-like syndrome were found in almost all, hypertrophic olivary nucleus degeneration
in all patients reported so far. The clinical course in pediatric patients is characterized by an initially unspecific
developmental delay, followed by regression, progressive signs and symptoms of cerebellar, basal ganglia and
brainstem affection, especially loss of speech and ataxia. Subsequently, neurological deterioration leading to a
vegetative state occurs.
Conclusions: Our findings add to the phenotypic, genetic, and biochemical spectrum of TTC19 deficiency.
However, TTC19 deficient patients do show characteristic clinical and neuroimaging features, which may facilitate
diagnosis of this yet rare disorder. Normal MRC complex III activity does not exclude the diagnosis.
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TTC19 (GeneBank: NM_017775; OMIM: 613814) en-
codes the tetratricopeptide repeat domain 19 consisting
of 380 amino acids. The TTC19 protein (NP_060245)
has been characterized as a high molecular weight com-
plex, which is embedded in the inner mitochondrial
membrane and has been reported to be involved in the
assembly and activation of mitochondrial respiratory
chain (MRC) complex III [1].
Recently, mutations in TTC19 have been described in
young adults with spinocerebellar ataxia [2-4], a 42-year-
old man with rapidly progressive neurological disease [1],
and patients with developmental delay in childhood and
slowly progressive neurodegenerative disease [1,5,6]. So far,
12 cases are documented in the literature. In all of them,
TTC19 loss-of-function mutations (4 nonsense mutations,
1 deletion of 4 base pairs, 2 duplications of 2 and 17 base
pairs, respectively) have been identified leading to prema-
ture protein truncation or nonsense-mediated RNA decay.
The biochemical feature indicative for mutations in
TTC19 is an isolated deficiency of mitochondrial respira-
tory chain (MRC) complex III [1-4,6]. Severe lactic acid-
osis in blood has not been reported in these patients.
Neuroimaging appears to be quite specific with
magnetic resonance (MR) showing T2-weighted signal
hyperintensities of caudate nucleus, putamen, and infer-
ior olives in the medulla oblongata as well as atrophy of
pons and cerebellum.
We describe the clinical, biochemical, and molecular
phenotypes of four pediatric patients with TTC19 defi-
ciency identified by exome sequencing and selective muta-
tion analysis, respectively. We aim to highlight the features
of disease manifestation in childhood in order to facilitate
diagnosis. For the first time, missense mutations in TTC19
are reported in patients, as well as a TTC19 deficient pa-
tient with a normal activity of the MRC III complex.
Methods
Patients
Patients 1 and 2 were recruited at a tertiary university
children’s hospital (Paracelsus Medical University,
Salzburg), patients 3 and 4 at a regional tertiary referral
hospital (Klinikum Reutlingen). Both hospitals are special-
ized in mitochondrial diseases and are partners of the
international MITONET research program.
All clinical data and samples were obtained with writ-
ten informed consent of the patients’ parents. The eth-
ical committee of the Technische Universität München
approved the exome sequencing studies.
Neuroimaging
MR imaging was performed on a 3-T magnet system
(Siemens Healthcare, Erlangen, Germany) and 1.5-T
magnet system (GE Healthcare, Reutlingen).Images were reviewed by a pediatric neuro-radiologist
and a pediatric neurologist.
Exome sequencing and molecular analysis of the
TTC19 gene
Total genomic DNA was extracted by standard methods
from peripheral blood lymphocytes using standard
protocols.
In patients 1 and 2 exome sequencing and variant fil-
tering was essentially performed as described previously
using a SureSelect Human All Exon 50 Mb V5 kit
(Agilent) for enrichment, and a HiSeq2500 (Illumina) for
sequencing (PMID 24461907). Read alignment to the
human genome assembly hg19 (UCSC Genome Browser)
was done with Burrows-Wheeler Aligner (BWA, v.0.7.5).
Detection of genetic variation was performed using
SAMtools (v 0.1.18), PINDEL (v 0.2.4 t), and ExomeDepth
(v1.0.0). Variant filtering was based on a presumed
autosomal-recessive mode of inheritance and focused on
homozygous and predictively compound heterozygous rare
nonsynonymous variants (MAF < 0.1% in 4,500 control
exomes). Identified TTC19 variants were confirmed by
Sanger sequencing.
In family 3 (patients 3 and 4), only sequencing of the
TTC19 gene was performed due to clinical suspicion of
TTC19 deficiency. The 10 exons and exon-intron boundar-
ies of TTC19 (GeneBank: NM_017775; NP_060245;
OMIM: 613814) were amplified using intronic primers and
subsequently sequenced on the forward and backward
strand. All primer sequences are available on request.
Expression analysis of TTC19
Total cellular RNA was isolated from muscle debris
using (TRI-reagent, MRC Inc.). RNA was reversely tran-
scribed with random hexamer primers (Maxima RT,
Thermo Scientific) and used for subsequent qPCR
analysis. PCR reactions were set up with iQ SYBR
Green SuperMix (Biorad) and performed in an iCycler
iQ5 (BioRad Laboratories). Three pairs of oligonucleo-
tides were designed to flank either the predicted mis-
sense mutation c.554 T > C (p.Leu185Pro) in exon 6
(Exon4-forward 5′-ATACGGGGTCAGCTTGAAAA-3′
and Exon7-reverse 5′-TGCAGAATTCATAGCCAG
CA-3′) or the predicted missense mutation c.971 T > C
(p.Leu324Pro) in exon 9 (Exon7/8-forward 5′-GACACC
CACAGACCATTGTG-3′ and Exon10-reverse 5′-CAG
CTTTGCTTGCTTCAGTG-3′). In addition, a third pair
of primers from exon 8 to 9 (Exon8-forward 5′-CGAGG
CAGAGATCATCCAG-3′ and Exon9-reverse 5′-CCAG
GGTAGTAGCCAGGTCA-3′) was designed. Two house-
keeping genes HPRT (HPRT-forward 5′-TTCCTTGGT
CAGGCAGTATAATC-3′ HPRT-reverse 5′-GGGCATAT
CCTACAACAAACTTG-3′) and RPL27 (RPL27-froward
5′-GCTGGAATTGACCGCTACC-3′ and RPL27-reverse
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as controls. All experiments were performed in duplicates.
To calculate ΔCt (difference of cycle thresholds), the mean
values of the housekeeping gene reactions were subtracted
from the respective TTC19 reactions. The ΔΔCt value was
calculated by subtracting the ΔCt values of the controls
from those of the patients.
Biochemical studies
Skeletal muscle tissues were homogenized in extraction
buffer (20 mM Tris–HCl, pH 7.6, 250 mM sucrose,
40 mM KCl, 2 mM EGTA) and subsequently centrifuged
at 600 g generating the postnuclear supernatant (600 g
homogenate), which was used for measurement of MRC
enzyme activities and western blot analysis.
MRC enzyme activities were determined as published
elsewhere [7-9]. Briefly, rotenone-sensitive complex I activ-
ity was measured spectrophotometrically as NADH/
decylubiquinone oxireductase. The enzyme activities of cit-
rate synthase, complex IV (ferro-cytochrome c/oxygen oxi-
doreductase), and the oligomycin-sensitive ATPase activity
of the F1F0 ATP synthase (complex V) were measured in
buffer conditions described by Rustin et al. [10]. Succinate
dehydrogenase activity (SDH; complex II) was determined
according to Rustin et al. with slight modifications [10].
Buffer conditions and procedure of determination of com-
plex III activity can be retrieved in Feichtinger et al [9]. All
spectrophotometric measurements were performed at 37°C.
Immunoblotting
For western blot analysis, a total of 10 μg protein of
600 g homogenate was separated on 10% acrylamide/
bisacrylamide gels and transferred to nitrocellulose mem-
branes using CAPS buffer. Washing and blocking proce-
dures were performed as previously described [10].
The following primary antibody dilutions, incubation
times and temperatures were used: monoclonal rabbit
anti-TTC19 (1:1,000; 1 h, room temperature; Abcam),
monoclonal mouse anti-UQCRC1 (Core 1) (1:1,000; 1 h,
room temperature, MitoSciences), monoclonal mouse
anti-UQCRFS1 (1:1,000; 1 h, room temperature;
MitoSciences), monoclonal mouse anti-porin (1:2,000,
2 h, room temperature; MitoSciences). After washing, the
membranes were incubated with secondary antibodies as
follows: UQCRC1, UQCRFS1 and porin with labeled
polymer-HRP-antimouse (1:1,000; 1 h, room tem-
perature, EnVision kit, Dako), TTC19 with labeled
polymer-HRP-anti-rabbit (1:1,000; 1 h, room temperature,
EnVision kit, Dako). Detection was carried out with Lumi-
LightPLUSPOD substrate (Roche).
BN-PAGE (blue native polyacrylamide gel electrophoresis)
Solubilized mitochondrial membranes were prepared from
isolated fibroblast mitochondria as described previously[11]. Briefly, fibroblast mitochondria were sedimented
by centrifugation at 13,000 g for 15 min. Membranes
were solubilized with 1.5% laurylmaltoside for 15 min
and centrifuged for 20 min at 13,000 g. Solubilized
membranes were loaded on a 5% to 13% polyacryl-
amide gradient gel and separated electrophoretically.
For immunoblot analysis, membrane preparations were
separated by BN-PAGE (5-13%) and blotted onto polyvi-
nylidene difluoride membrane (Hybond-P, GE Healthcare)
using a CAPS buffer (10 mmol/l 3-cyclohexylamino-1-
propane sulfonic acid pH 11, 10% methanol). The mem-
brane was washed in 100% methanol for 2 min and
blocked for 30 min at room temperature in 1% blocking
solution (Roche) dissolved in TBS-T. The primary anti-
bodies, diluted in 1% blocking solution-TBS-T, were added
1 h at room temperature. The following primary antibody
dilutions were used: complex I subunit NDUFS4 mono-
clonal antibody (1:1,000; MitoSciences) complex V subunit
α monoclonal antibody (1:1,000; MitoSciences) and com-
plex II subunit SDHA monoclonal antibody (1:30,000;
MitoSciences). After extensive washing, blots were incu-
bated for 1 h at RT with secondary mouse antibody
(1:100; DAKO polymer Envision Staining Kit). Detection




Clinical, biochemical, and molecular data of the 4 pa-
tients with TTC19 mutations is summarized in the
Table 1.
Patient 1
Patient 1, a boy, was born by caesarian section to
healthy, consanguineous Turkish parents after unevent-
ful pregnancy (birth weight 3620 g, length 50 cm, head
circumference 35 cm, APGAR 9/10/10). The boy had
four older healthy siblings (1 sister, 3 brothers). He pre-
sented with severe lactic acidosis in the neonatal age and
during intercurrent infections at the age of 4 months
(RSV), 5 months (viral infection), 10 months (tonsillitis),
and 16 months (complicated febrile seizure). Lactic acid
levels were normal in repeated analyses between the in-
fections. The boy’s psychomotor development was glo-
bally delayed. He never walked independently. In his
second year of life, regression occurred starting with a
loss of speech and vocalizing at age 13 months, massive
muscular hypotonia and muscle weakness.
T2-weighted MR imaging at the age of 16 months re-
vealed symmetric hyperintensities of the basal ganglia
and the periventricular white matter. Skeletal muscle bi-
opsy showed signs of mitochondrial involvement, e.g.
numerous ragged red fibers and low COX reaction, and
partially reduced activities of MRC complexes II and III.
Table 1 Clinical, biochemical, and molecular findings of the 4 patients with TTC19 deficiency
Patient 1a Patient 2a Patient 3b Patient 4b
Sex male male male female
Ethnic origin Turkish Austrian Romani Romani
Age at onset of symptoms neonatal 19 months 3 years 6 years








Current clinical condition 10 years, alive, vegetative
state, refractory epilepsy,
bilateral spasticity







7 years, motor skills
delayed, normal
schooling
TTC19 mutations (homozygous)c c.971T>C; p.Leu324Pro c.656T>G; p.Leu219*d c.554T>C; p.Leu185Pro c.554T>C; p.Leu185Pro
Muscle biopsy not performed
MRC complex III activity % of Lowest Control 28% 31% normal
Absolute value (reference range) 0.40 (1.45-3.76) 0.45 (1.45-3.76) 1.49 (1.45-3.76)
Western blotting TTC19 trace trace trace
Complex III, core 1 normal normal normal
Complex III, core 2 normal normal normal
Complex III, Rieske normal normal normal
Metabolic data
Elevated lactate (blood/CSF) + / n.a. + / n.a. - / - -
Neurological status
Ataxia + + + -
Dysphagia + + + -
Dysarthria + + + -
Dystonia + + - -
Enhanced tendon reflexes + + + +
Spasticity + + + -
Hypotonia + + + +
Symptomatic epilepsy + - + -
Regression/decline + + + -
Loss of speech + + + -
Neuroimaging features
Leigh syndrome + + + -
Hyperintensities (T2-weighted) N. caudatus + + + +
Putamen + + + +
Medulla oblongata + + + -
Mesencephalon + + + -
Olivary nucleus + + + -
Leukoencephalopathy + + n.a. -
Cerebellar atrophy + + + (+)
Pontine atrophy - - - -
Cortical atrophy + + + -
1H-MRS (lactate peak) n.a n.a + n.a.
Abbreviations are as follows: n.a., not available; MR, magnetic resonance; 1HMRS, proton magnetic resonance spectroscopy; Enzyme activities were normalized to
citrate synthase (CS). Absolute values and reference ranges are given in (mU/mU CS).
aInvestigated by exome sequencing.
bThese individuals are siblings.
ccDNA (NM_017775);Protein (NP_060245).
dMutation was previously published [1].
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tertiary University hospital for second opinion and fur-
ther diagnostic work-up at the age of 2 years. A second
muscle biopsy was performed revealing normal PDH
activity and normal pyruvate oxidation, but signifi-
cantly decreased isolated MRC complex III deficiency
with a residual activity of 28% of the lowest control.
The findings of ragged red fibers and low COX reac-
tion were not confirmed. Using exome sequencing, the
novel missense mutation c.971 T > C (p.Leu324Pro)
was identified in a homozygous state. The mutation af-
fects the conserved tetratricopeptide repeat (TPR) do-
main 5 (Figure 1A).
MR imaging at the age of 4 years showed a rapid
progression with bilateral signal hyperintensities inA
B
Figure 1 Mutations in TTC19 and expression of TTC19. A. Novel and
A schematic drawing shows the 10 exons, the mitochondrial targeting s
The previously reported mutations are indicated in black, the two novel
alignment with different species shows the affected amino acid residue
patients (P) and controls (C). Normal amounts of TTC19 transcripts comp
mutations (c.971 T > C; p.Leu324Pro and c.554 T > C; p.Leu185Pro). A sig
who carries the stop mutation c.656 T > G (p.Leu219*). A repeated meas
was used for statistical analysis (**p < 0.01).T2-weighted images of the basal ganglia (putamen,
pallidum), thalamus, the mesencephalon, and the medulla
oblongata with hypertrophic olivary degeneration as well
as severe cerebellar atrophy (Figure 2, column 1).
The boy is now 10 years old. Since the age of 8 years,
he is unable to communicate showing only unspecific re-
actions to pain. He is severely hypotonic and lacks any
postural control. He is completely immobile with no
spontaneous movements but moderate bilateral spasti-
city of the limbs. He requires feeding via a gastric tube.
His main medical issues are refractory epilepsy with pre-
dominantly tonic seizures and recurrent airway infec-
tions. Currently, he is treated with antiepileptic drugs
and carnitine, supplementation with coenzyme Q10 and
riboflavin has been ceased.reported Mutations in TTC19 and their phylogenetic conservation.
equence (MTS), and the 5 tetratricopeptide repeats (TPR) of TTC19.
missense mutations reported here are highlighted in red. Sequence
s to be highly conserved. B. TTC19 transcript levels in muscle of
ared to controls were found in patients 1 and 3 carrying missense
nificant reduction of TTC19 transcripts was observed in patient 2
ures ANOVA and a Tukey post test to compare all pairs of columns
Figure 2 Brain magnetic resonance imaging of the four patients. Hyperintensities in T2 (Flair 2a, 1b)-weighted images indicate pathology of
basal ganglia (1a, 2a, 3a, 4a), thalamus (1a), and mesencephalon (1b). Cerebellar atrophy is shown on in 1b, 2b, 3b. The increased interfoliar
spaces in 4b may be interpreted as early sign of cerebellar atrophy in the clinical context of patient 4. Hypertrophic degeneration of olivary nuclei
are marked with red arrows in 1c, 2b and c (T1 signal hypointensity), 3b and c. It is not seen in 4b, c.
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Patient 2, a boy, is the only child of a single Austrian
mother, who reported tobacco and drug use during preg-
nancy. The ethnic background of the father is unknown.
The boy was born at term (3895 g, 55 cm length, 38 cm
head circumference; APGAR 9/10/10) followed by an
uneventful postnatal period.
In his 3rd month of life, he presented with an episode
suspicious of convulsion, but diagnostic work-up was
unremarkable. At the age of 19 months, a global devel-
opmental delay regarding motor skills, speech, and social
contact was documented. In addition, muscular hypo-
tonia, muscle weakness as well as disturbed coordination
were described.
Until the age of 6 years, a constant developmental
delay with dyspraxia, dysarthria, and lack of initiativeand motivation were noted. Neuroimaging by T2-
weighted MR showed bilateral hyperintensities within
the putamen, the caudate nucleus and the periaqueduc-
tal gray matter of the mesencephalon. At the age of
7 years, he presented with rapidly progressive ataxia,
dysarthria, and dysphagia. His deep tendon reflexes were
exaggerated, the muscle tone reduced. Laboratory find-
ings including CK, liver parameters, lactic acid, acylcar-
nitines, and amino acids were normal. MRI of the brain
revealed a considerable progression of the pathologies
with respect to basal ganglia, mesencephalon, pons, me-
dulla, and cerebellum. T2 weighted images showed sig-
nal hyperintensities with “cystic” aspects in caudate
nucleus and putamen, increased T2 signaling in the pos-
terior medial thalamus, the mesencephalon with the
periaqueductal gray matter, and hypertrophic olivary
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cleus, as well as cerebellar atrophy (Figure 2, column 2).
Skeletal muscle biopsy and analysis of respiratory
chain enzymes indicated isolated deficiency of complex
III (31% of lowest control) without signs of mitochon-
drial disorder in histology and histochemistry. Exome se-
quencing identified the previously described nonsense
mutation c.656 T > G (p.Leu219*) was shown in a homo-
zygous state [1].
The boy is now 9 years old, his clinical condition
showing a constant decline. He is wheelchair-bound due
to bilateral spasticity and dystonia. Only little activity is
remaining in his left arm and hand. He lost speech and
is able to communicate only yes and no. Due to severe
dysphagia, he requires to be fed via a gastric tube. He is
supplemented with antioxidative medication (carnitine,
coenzyme Q10, thiamine, riboflavin).
Patient 3
Patient 3, a boy, is the 2nd child of healthy parents. He
was born after a normal full-term pregnancy. The post-
natal period was unremarkable. The mother grew up in
Macedonia, the father in Croatia. Both parents belong to
the ethnic group of Romani people. The boy has 3
healthy siblings (16, 2 ½, and 1 years of age). A 7-year-
old sister (patient 4) shows mild muscular hypotonia
and retardation of motor skills.
Family history was remarkable for deafness of two
cousins of the mother, for trisomy 21 of one cousin of
the mother, and for a remote male relative showing
similar signs and symptoms as patient 3 (no clinical
data available).
Since the family lived in several European countries,
there was no constant follow-up by a family doctor.
According to the parents, the boy’s initial psychomotor
development was normal. He started to walk independ-
ently at the age of 15 months, however, spoke his first
words not before the age of 2 years. At the age of 3 years,
he started kindergarten (nursery school), where a de-
layed statomotor development with frequent stumbling
was stated. First grade of primary school had to be re-
peated two times. At the age of 8 years, neurological de-
terioration and regression occurred beginning with a
loss of speech, followed by disturbed gait and paresis. By
the age of 11 years, he had lost almost all of his acquired
skills, and was wheelchair-bound. He communicated
with his eyes, facial expressions, and little hand move-
ments using a tablet computer.
MR imaging at the age of 9 years revealed hyperin-
tensities of nucleus lenticularis and nucleus caudatus
suspicious for mitochondrial disease, a follow-up
neuroimaging 2 ½ years later a loss of volume in the
putamen, and signs of cerebral atrophy. MR spectros-
copy showed a clearly elevated lactic acid peak withreduced NAA. Lactic acid in cerebrospinal fluid (CSF)
was normal.
Skeletal muscle biopsy was unremarkable with normal
activities of the MRC enzymes and no signs of mito-
chondrial disease in histology and histochemistry.
Following a non-febrile upper respiratory tract infec-
tion at the age of 14 years, the boy developed sepsis and
rapidly deteriorated with severe muscular hypotonia,
tachycardia, dysphagia, and difficulties in breathing oc-
curred. He was admitted to the intensive care unit of a
tertiary hospital specialized on mitochondrial disease for
further treatment and diagnostic work-up. No lactic
acidosis was reported during this episode.
MR imaging revealed inhomogenous hyperintensities
of the striatum (caput nuclei caudate, putamen), hyper-
intense hypertrophic degeneration of the right infer-
ior olivary nucleus, and cerebellar atrophy (Figure 2,
column 3). Analysis of a second muscle biopsy showed un-
specific impairment of mitochondrial energy metabolism
but no deficiency of MRC complexes.
Due to the MR imaging and lack of lactic acidosis,
western blotting of TTC19 protein was performed re-
vealing only traces of TTC19 protein. Subsequent se-
quencing of TTC19 showed a novel missense mutation,
c.554 T > C (p.Leu185Pro) in a homozygous state. The
mutation affects a conserved position in the TPR do-
main 2 (Figure 1A).
The boy is now 14 years old. He shows severe bilateral
spasticity and refractory symptomatic epilepsy. Only lit-
tle spontaneous movements of the upper extremities are
seen. Because of muscular hypotonia and dysphagia,
feeding via a PEG tube is required. He is treated with an
antiepileptic drug (levetiracetam) and is supplemented
with coenzyme Q10 and thiamine.
Patient 4
Patient 4, a girl, is the younger sister of patient 3. She
was born after a normal full-term pregnancy (birth
weight 3500 g). Her initial psychomotor development
was normal, with sitting at the age of 7–8 months, first
walking at the age of 13 months, and first words at the
age of 9 months. At the age of 6 years, due to muscular
hypotrophy of the legs, MR imaging was performed with
normal results (no data available).
After her brother’s diagnosis was identified, the girl
was re-evalutated. She attends primary school with suffi-
cient success. On neurological examination, she shows
muscular hypotonus, brisk tendon reflexes, delayed fine
motor skills, but no ataxia.
MR imaging at the age of 7 years showed hyperintensi-
ties in caput nucleus caudati and basal parts of the puta-
men, as well as increased interfoliar spaces in the
cerebellum (Figure 2, column 4). This abnormal find-
ing may be interpreted as an early sign of cerebellar
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unaffected.
Subsequent sequencing of TTC19 showed the same
novel missense mutation, c.554 T > C (p.Leu185Pro), in
a homozygous state as her brother. The girl is supple-
mented with coenzyme Q10, thiamine, and biotin.
Biochemical and molecular findings
Exome sequencing and Sanger sequencing, respectively,
revealed TTC19 mutations in all four patients (Table 1).
In patients 1 and 2 investigated by exome sequencing, a
filter for rare recessive-type nonsynonymous variants
identified 28 and 6 genes, respectively. In both cases,
TTC19 was the only gene coding for a protein with a
confirmed or predicted mitochondrial localization ac-
cording to a MitoP2 score >2.5 [12]. All mutations were
found in the homozygous state in the patients and con-
firmed in the heterozygous state in the parents (except
for patient 2, whose father is not known to us). Two mu-
tations (c.971 T > C, c.554 T > C) are novel and the first
reported pathogenic missense mutations in TTC19,
whereas the nonsense mutation c.656 T > G has been
described previously [1] (Figure 1A). The two missense
mutations are not present in >122.000 control alleles of
the Exome Aggregation Consortium (ExAC) BrowserA
B
Figure 3 Western blot analysis of muscle homogenisates and fibroblast
TTC 19 protein in markedly reduced in patient 1 and absent in patients 2 and
subunits of MRC complex III, in comparison to porin. Porin is a protein of the o
Native-PAGE: There is no obvious reduction of complex III (CIII, core 2) in patie
V (CV, ATP5A1) were used as loading controls.(Cambridge, MA (URL: http://exac.broadinstitute.org)
12/2014) while the nonsense variant c.656 T > G is listed
5 times in 122.582 alleles, however, only in the heterozy-
gous state. The expression of TTC19 mRNA in muscle
was investigated by quantitative real-time PCR and re-
vealed a normal amount of cDNA in case of the two
missense mutations (patient 1 and patient 3) (Figure 1B).
The size of the products was normal, too (data not
shown). In case of patient 2, carrying the nonsense mu-
tation c.656 T > G (p.Leu219*), the amount of cDNA
was significantly decreased (ΔΔCt = 1.8) pointing to
nonsense-mediated decay of this RNA (Figure 1B).
Our patients showed an isolated deficiency of MRC
complex III, except for patient 3, who demonstrated nor-
mal activities of MRC complex III in two independent
muscle biopsies (Table 1). In western blot analysis,
TTC19 protein was severely reduced (patient 1, fibro-
blasts) or not detectable in patients 2 and 3 (skeletal
muscle and fibroblasts) (Figure 3A). The additionally
tested subunits of complex III, namely core 1 and Rieske
protein were detectable in normal amounts, as well as
porin (Figure 3A). BN-PAGE experiments in fibroblast
mitochondria revealed that complex III is fully assem-
bled in all three patients compared to complex II and
complex V (Figure 3B).mitochondria of TTC19 patients (P) and controls (C). A. SDS-PAGE:
3. There is no obvious reduction in core 1 and Rieske protein, both
uter mitochondrial membrane and was used as a loading control. B: Blue
nts 1, 2, and 3 compared to controls. Complex II (CII, SDHA) and complex
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Mutations in TTC19 have been described in 12 patients
from eight families so far [1-6]. Seven of these patients
showed disease manifestation in adulthood, six of them
presenting with progressive cerebellar ataxia and dys-
arthria, variably accompanied by mental impairment and
psychiatric manifestations [2-4]. Another patient showed
subacute, rapidly progressing neurodegeneration at the
age of 42 years, leading to death within 2 years [1].
Patients with an infancy-onset disease displayed a pro-
gressive neurodegenerative disorder [1,6] and global de-
velopmental delay followed by language regression [5].
In this report, we describe the clinical, biochemical,
and molecular data of four new pediatric patients with
TTC19 deficiency from three unrelated families. First
clinical features were unspecific in all patients consisting
of global developmental delay, delayed motor skills, and
muscle hypotonia (Table 1). Subsequently, progressive
signs and symptoms of cerebellar, basal ganglia and
brainstem affection were observed such as ataxia, dys-
arthria, aphasia, dysphagia, dystonia and spasticity in the
severely affected patients 1, 2, and 3. Neurological de-
terioration occurred at different progression rates leading
to severe motor and cognitive impairment in patients 2
and 3. Patient 1 is in a minimally conscious state, patient 4
presumably in an early stage of the disease.
The clinical course of the patients described herein co-
incides very well with the disease manifestation of the
three patients with an onset of disease in infancy re-
ported by Ghezzi et al. A striking common finding in
our patients was regression beginning with an early and
pronounced loss of speech in all three severely affected
patients 1, 2, and 3. Loss of speech is not a frequent
neurological finding in pediatric patients, but may be a
characteristic finding for TTC19 deficiency and thus, a
hint for diagnosis. It was indicated as major finding inFigure 4 Main clinical, biochemical, and MRI features in 14 patients w
and laboratory findings, the X axis indicates the frequency (%). The figure s
this work is not included, as she is still oligosymptomatic. Remarkably, elev
isolated MRC complex III deficiency is not a constant finding in all patientsthe 4-year old boy described by Atwal et al. as well as in
2 of 3 patients described by Ghezzi et al. In the patient
reported by Melchionda et al. it was a rather late symp-
tom. Figure 4 summarizes the major clinical, biochem-
ical, and neuroimaging features of 14 TTC19 patients
reported so far [1-3,5,6], which appear to be quite char-
acteristic, to draw the clinicians’ attention to a potential
diagnosis of TTC19 deficiency.
Interestingly, patient 1 showed severe lactic acidosis in
the neonatal age as well as during intercurrent viral in-
fections thereinafter. Neonatal lactic acidosis is found in
several types of mitochondrial disorders [13], but has
not been associated with TTC19 deficiency so far. Pa-
tients with TTC19 deficiency have been described to
show normal or only slightly elevated concentrations of
lactic acid in blood [1,2,6].
At the age of 7 years, patient 4 shows only mild and
unspecific neurological impairment. She was diagnosed
with TTC19 deficiency in the context of her brother’s
(patient 3) rapidly deteriorating clinical course. At the
moment, it is difficult to predict the onset of further
symptoms as well as the rate of progression. Even within
the same family, the clinical phenotype has been
reported to vary significantly in patients with TTC19 de-
ficiency [3], as in other mitochondrial disorders associ-
ated with neurodegeneration [14-16].
MR imaging of our patients revealed symmetrical hy-
perintense lesions of the basal ganglia, thalami, brain-
stem, and the cerebellum on T2-weighted images
consistent with Leigh syndrome [17] and, thus, led
to the diagnostic workup for mitochondrial disease.
However, the genetic background of Leigh syndrome is
heterogeneous and often remains unsolved despite ex-
tensive investigations [16]. In addition to MRI patterns
consistent with Leigh syndrome, our severely affected
patients 1, 2, and 3 showed hypertrophic olivaryith TTC19 deficiency. The y axis lists the main clinical symptoms, MRI
ummarizes 14 patients reported in the literature [1-3,5,6]. Patient 4 of
ated blood lactate is found in less then fifty percent of patients and
.
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Hypertrophic olivary degeneration is a rare finding in
pediatric patients [18]. It results from lesions within the
dento-rubro-olivary pathway and has been reported in
children after tumor surgery in the posterior fossa and
the brainstem [19-23]. Furthermore, recent studies sug-
gest, that hypertrophic olivary degeneration in children
is associated with mitochondrial disease, especially with
Leigh and Leigh-like syndrome [18,24-28]. In a cohort of
125 children with mitochondrial and genetic disorders,
hypertrophic olivary degeneration was found in 40% of
patients with Leigh or Leigh-like syndrome (10/25), but
not in patients with other mitochondrial (0/25) or gen-
etic (0/75) disorders [18]. Mutations in SURF1 and
POLG have been identified in patients with mitochon-
drial disease and hypertrophic olivary degeneration, but
are not a consistent finding [18,25,28]. In patients with
Leigh syndrome due to mutations others than SURF1
and POLG, hypertrophic olivary degeneration is hardly
found [18] with the exception of one case of PDH defi-
ciency [26]. Remarkably, hypertrophic olivary degener-
ation is a consistent finding in our severely affected
patients (Figure 2) and in nine out of ten previously
published patients with TTC19 mutations who under-
went MR investigation [1-5]. The patient reported by
Melchionda et al. showed no hypertrophic olivary degen-
eration in neuroimaging that was done at a relatively
early stage of the disease. We suggest that hypertrophic
olivary degeneration in patients with Leigh or Leigh-like
lesions in brain MRI is – in addition to SURF1 and
POLG - a strong diagnostic indication for TTC19
mutations and thus can facilitate diagnostic workup.
However, hypertrophic olivary degeneration can be
very subtle on MR imaging and may be missed if not
intently looked for.
Hypertrophic olivary degeneration has been described
to be clinically associated with palatal tremor and myo-
clonus [28,29], a finding that has not been found in our
patients. One might, however, speculate that the clinical
signs of dysarthria, loss of speech and dysphagia are conse-
quences of an impaired palatal function in hypertrophic
olivary degeneration to some extent. Furthermore, the in-
ferior olivary nucleus has shown to be involved in the
pathogenesis of ataxia in mitochondrial disorders and to be
vulnerable to energy deprivation with a clinical presenta-
tion most often after first year of life [30-32].
Patient 4, the so far mildly affected sister of patient 3,
showed unremarkable inferior olives at the age of 7 years,
but development of hypertrophic olivary degeneration
needs to be carefully followed-up in correlation with first
clinical signs of ataxia and disturbance of speech.
Consistent with previous reports [1-6], cerebellar atro-
phy was found in our patients, but no increased signals
in the dentate nucleus (Figure 2).The TTC19 mutations identified in our patients differ
considerably from the mutations previously reported. So
far, only nonsense and frameshift mutations due to small
deletions and duplications have been described [1-5].
Both kinds of mutations are regarded deleterious as they
result in a premature stop codon subjecting the gener-
ated mRNA to nonsense-mediated mRNA decay [33] or
the translation of substantially truncated proteins.
For the first time, we identified two novel missense
mutations (c.971 T > C; p.Leu324Pro and c.554 T > C;
p.Leu185Pro) in three of our patients (patients 1, 3,
and 4), thus expanding the mutational spectrum of
patients with TTC19 mutations. The quantification of the
TTC19 cDNA in these patients showed a similar amount
compared to controls, which indicates a stable transcript
for these missense mutations. Both mutations are localized
within tetratricopeptide repeats that are conserved within
TTC19 proteins. The replacement of leucine for proline,
which was found in both missense mutations, is expected
to affect the helical structure of these TPR domains. Not-
ably, the missense mutation in patient 1 was associated
with an early and previously not reported onset of disease
in terms of neonatal lactic acidosis and lactic acidosis dur-
ing intercurrent febrile infections.
The nonsense mutation c.656 T > G (p.Leu219*),
which was found in patient 2 has been previously de-
scribed in two families [1], and is the only recurrent mu-
tation in TTC19 so far.
So far, the biochemical indication for TTC19 defi-
ciency has been MRC complex III deficiency [1-3,5,6],
either isolated [2,3] or in combination with other MRC
complexes [5]. This finding is in agreement with our pa-
tients 1 and 2. In patient 3, however, activity of MRC
complex III was normal in two independent muscle bi-
opsies analyzed in different metabolic centers. In this pa-
tient, diagnosis of TTC19 deficiency would have been
missed if mutational or western blot analysis was only
taken in account in patients with MRC complex III defi-
ciency. To our knowledge, this is the first patient with
TTC19 deficiency showing a normal MRC complex III
activity. Furthermore, the amount of complex III and its
subunits (core 1, core 2, and Rieske protein) in Blue
Native and SDS electrophoresis was found to be normal
in patients 1, 2, and 3 (fibroblasts, muscle), which com-
plicates the diagnosis of TTC19 deficiency.
Conclusions
TTC19 deficiency is a rare but maybe underdiagnosed
mitochondrial disorder. We present four pediatric patients
from 3 unrelated families 3 of them being severely af-
fected. For the first time, we describe homozygous mis-
sense mutations in TTC19 patients, as well as one patient
presenting with episodes of severe lactic acidosis, and one
patient with normal MRC complex III activity. Thus, we
Koch et al. Orphanet Journal of Rare Diseases  (2015) 10:40 Page 11 of 12expand the genetic, clinical, and biochemical spectrum of
the disease. Reviewing the literature, we delineate very
characteristic clinical, biochemical, and neuroimaging fea-
tures, which should alert clinicians to the possibility of the
diagnosis TTC19 deficiency.
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